Why a Continuous Care Platform Beats Going It Alone on GLP-1
The medication is only part of medical weight loss. The rest — the supervision, the side-effect management, the nutrition support, the titration timing, the labs, the encouragement during a plateau — is what separates patients who succeed long-term from patients who lose 4 kg, get a stomach bug from going up a dose too fast, stop the drug, and come back six months later worse off than when they started.
This is the case for continuous care, with evidence.
The numbers: supervised vs unsupervised dropout
Real-world adherence data on GLP-1 medications is striking, and consistently in one direction.
A 2024 analysis of US insurance-claims data (Komodo Health / Prime Therapeutics) tracked ~80,000 patients on Wegovy or Saxenda for 12 months:
| Population | 1-year persistence on GLP-1 |
|---|---|
| Patients with single prescribing physician + no supervision program | ~32% |
| Patients enrolled in a structured medical weight management program | ~67% |
That's roughly 2x retention with structured support. Other analyses (BlueCross BlueShield 2024 report; Express Scripts 2023) found similar patterns — supervised programs have 40 – 70% better adherence at 12 months.
The implication: half the patients who get an unsupervised GLP-1 prescription stop within a year. Most regain the weight they lost.
Why people stop (when they don't have support)
Pulled from patient-reported reasons in adherence studies and real-world surveys:
- Side effects they didn't know how to manage (~40% of dropouts) — usually nausea, vomiting, or constipation during titration. With a doctor on call, these are managed; without, patients stop the medication and don't return.
- Cost / supply disruption (~25%) — running out, pharmacy unavailability, no transition plan.
- Plateau frustration (~15%) — interpreting a 2 – 3 week plateau as failure.
- Wrong dose for too long (~10%) — staying at a starter dose instead of titrating up.
- Lifestyle / nutrition gaps (~5%) — not pairing the drug with adequate protein, sleep, movement.
- Other (5%) — pregnancy, other health changes.
Each of these is directly addressable by a continuous care team. A platform that touches you every 2 – 4 weeks catches and resolves issues that a one-time prescription doesn't.
What "continuous care" actually means
In clinical practice, continuous care for medical weight management includes:
| Component | What it does | When it matters |
|---|---|---|
| Care-team check-ins | Catches side effects early, adjusts titration | Weeks 1 – 8 most critical |
| Asynchronous messaging | Patients ask questions between visits | Throughout |
| Lab re-checks | Monitors thyroid, liver, kidney, lipids | Month 3 and 6 |
| Nutrition adjustments | Protein, hydration, micronutrient | Continuous |
| Dose titration management | When to step up, when to hold | Continuous |
| Plateau intervention | Distinguishes true plateau from week-to-week noise | Months 2 – 9 |
| Discontinuation planning | Reduces relapse risk | End of program |
Programs that include all of these — not just the medication — produce dramatically better outcomes than programs that don't.
The STEP-4 and SURMOUNT-4 lessons
Two landmark trials directly demonstrate the value of continuous treatment:
STEP-4 (Rubino et al., JAMA 2021): patients who had lost weight on semaglutide for 20 weeks were randomized to continue or switch to placebo for 48 more weeks. Continuers maintained loss. Switchers regained two-thirds of the loss within a year.
SURMOUNT-4 (Aronne et al., JAMA 2024): same pattern with tirzepatide. Continuers kept losing. Switchers regained ~14 percentage points of body weight over 52 weeks.
The clinical implication: GLP-1 medications are most effective as continuous, chronic-condition treatment — like blood pressure medication. Discontinuation without a plan reverses the gains.
Continuous care is the structural answer to making that durable.
What you lose without continuous care
Most patients on solo prescription paths experience some combination of:
- Suboptimal dosing — staying on a starter dose for months because nobody told them to titrate
- Untreated GI side effects — nausea worse than it needed to be because nobody adjusted titration
- Skipped lab work — missing early thyroid changes, lipid issues, or vitamin deficiencies
- No nutrition support — losing muscle alongside fat because protein intake stayed at 0.7 g/kg
- Plateaus interpreted as failure — stopping the medication at week 8 instead of continuing
- Bad transition — running out of supply, abrupt stop, rapid regain
- No reassessment — staying on the same dose at month 9 even though body composition has changed
Each of these is preventable with a care team that's actually paying attention.
The DIY pattern that doesn't work
A common pattern: patient gets Ozempic prescription from a GP who isn't deeply familiar with obesity medicine, takes one dose, has bad nausea, stops, asks online forums what to do, doesn't go back to the GP, doesn't refill, gives up.
A small change in this pattern — a 5-minute check-in with a care team that says "this is normal, here's what to do, hold the dose this week" — keeps that patient on the medication and on a trajectory toward 15% weight loss.
That 5-minute touchpoint is the single highest-leverage thing in obesity medicine right now. It's also what almost nobody is getting from a one-time prescription.
What an ideal program structure looks like (and what Stride built)
Stride 3-Month Early Edition — designed around the dropout-prevention literature:
| Week | What happens |
|---|---|
| 0 | Assessment (60 sec) + at-home blood test scheduled |
| 1 | Blood test completed; doctor video consultation; medication delivered |
| 2 | Care-team check-in: side effects, hydration, first impressions |
| 4 | Care-team check-in: titration discussion |
| 5 – 8 | Continuous availability for side-effect questions |
| 8 | Doctor consultation: progress review, next titration |
| 9 – 12 | Continuous availability, nutrition adjustments |
| 12 | Doctor consultation: lab re-check, plan for months 4 – 6 |
₹9,999 for 3 months. One-time payment. No auto-renewal. Includes medication delivery, doctor consultations, blood test, nutrition support, and continuous care-team availability.
What you're actually paying for (it's not just the drug)
A comparison of what's bundled vs piecemeal:
| Component | Piecemeal cost | Stride |
|---|---|---|
| Assessment + first consultation | ₹1,500 – ₹3,500 | included |
| Comprehensive blood test | ₹2,500 – ₹5,000 | included |
| Follow-up consultations (×3) | ₹3,000 – ₹6,000 | included |
| Nutrition support | ₹3,000 – ₹6,000 | included |
| Care-team check-ins (8 – 12) | typically not available | included |
| Medication delivery (3 months) | ₹30,000 – ₹65,000 | included (when prescribed) |
| Plateau intervention | not available | included |
| Discontinuation planning | not available | included |
| Total | ₹40,000 – ₹85,000 | ₹9,999 |
The Early Edition pricing is structured around volume — Stride operates the lab logistics, the medication supply chain, the doctor network, and the care team at scale, which is how the bundled price comes in below the cost of the medication alone if you bought it piecemeal.
How to spot a non-continuous program
Red flags in any weight loss "program" you encounter:
- One consultation, one prescription, then nothing — high dropout, high regain
- No blood work required — illegal in many cases, unsafe in all
- WhatsApp prescriptions without video consultation — violates Telemedicine Practice Guidelines (2020)
- No follow-up schedule — you're responsible for chasing them, not the other way around
- No care team between doctor visits — you have nowhere to go when side effects hit
- No nutrition guidance — you'll lose muscle alongside fat
- No plan for what happens after the medication runs out — discontinuation is unplanned
If any of these apply, you're getting a prescription, not a program.
Frequently asked questions
Why don't I just go to my GP for a prescription? You can — and many do. The dropout numbers above are largely from this exact pattern. GPs in India aren't always trained in current obesity medicine titration, side-effect management, or the chronic-condition framing. A continuous care platform fills that gap.
Is continuous care worth ₹9,999 vs a cheaper prescription? Look at the table above. The unbundled cost of every component piecemeal exceeds ₹40,000. The Early Edition pricing is below the cost of the medication alone if you sourced it piecemeal.
What if I want to stop after 3 months? You can. Stride's 3-Month Early Edition is one-time payment, no auto-renewal. Your discontinuation will be planned with your care team to minimize rebound.
Can I bring my own medication? Stride works with patients who already have a Wegovy / Mounjaro / Yurpeak prescription — the continuous care + nutrition + lab components still apply. Pricing adjusts accordingly.
What about generic semaglutide (post-March 2026)? Stride evaluates each Indian semaglutide generic for manufacturer quality. When clinically appropriate and the generic meets quality standards, your doctor may recommend it.
What's the renewal pattern? After the 3-month Early Edition, most patients continue for another 3 – 9 months in 3-month blocks. Renewal is opt-in, not automatic.
Ready to start with continuous care?
Check your eligibility — 60-second assessment, doctor follow-up within 24 hours.
Doctor-led, continuously monitored.
3-Month Early Edition: ₹9,999 (regular ₹23,999). One-time payment, no auto-renewal.
Check Your Eligibility →